Modeling Malignant Mesothelioma in Genetically Engineered Mice
Current Protocols · 2025-01 · 5 (1)
DOI: 10.1002/cpz1.70086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Protocols, online erschienen am 10.01.2025. Verfasst von Yuwaraj Kadariya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. Hauptthemen laut MEDLINE: Mesothelioma, Disease Models, Animal, Mesothelioma, Malignant, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: ORFDO NIH HHS, NCI NIH HHS, CLC NIH HHS.
Abstract (Originalsprache)
Mesothelioma is a lethal cancer of the serosal lining of the body cavities. Risk factors include environmental and genetic factors. Asbestos exposure is considered the principal environmental risk factor, but other carcinogenic mineral fibers, such as erionite, also have a causal role. Pathogenic germline (heritable) mutations of specific genes, especially BAP1 , are thought to predispose the individual to mesothelioma in about 10% of cases. Somatic mutations and deletions of specific tumor suppressor genes, particularly BAP1 , CDKN2A/B , and NF2 , occur frequently in human mesothelioma, and asbestos‐exposed mice with heterozygous deletions of any one of these genes have been shown to develop mesothelioma more often and at an accelerated rate than in control animals. Autochthonous mesothelioma mouse models, which are genetically engineered to carry multiple genetic lesions matching those observed in the human disease counterpart, closely resemble the disease phenotype and the extensive inflammatory responses that characterize human mesothelioma. Because autochthonous mice do not require asbestos exposure and form tumors rapidly, these models are invaluable for assessing novel therapeutic strategies in an immunocompetent setting. The overlapping genetic, epigenetic, and immune environments of the tumors observed in these genetically engineered mouse models (GEMMs) and human primary mesothelioma specimens support the clinical relevance of these preclinical models. This article presents protocols for studies of asbestos‐induced mesothelioma in GEMMs and non‐carcinogenic conditional knockout models of mesothelioma, including an example of a preclinical application. These models are invaluable for understanding the biological underpinnings of mesothelioma and for testing new therapeutics and chemoprevention or interception agents. © 2025 Wiley Periodicals LLC. Basic Protocol 1 : Generation of a genetically engineered mouse model (GEMM) with a germline Bap1 knockout allele Basic Protocol 2 : Generation of GEMMs with germline Bap1 knock‐in alleles Basic Protocol 3 : Asbestos carcinogenicity investigations with GEMMs Basic Protocol 4 : Preclinical chemoprevention and chemotherapy studies using a GEMM with asbestos‐induced mesothelioma Basic Protocol 5 : Generation of a GEMM with conditional knockout of Bap1 Basic Protocol 6 : Generation of a conditional knockout model of mesothelioma
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
- Nuclear Dynamics and Cancer Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
ORCID-Profile: Joseph R Testa
Förderung
- ORFDO NIH HHS
- NCI NIH HHS
- CLC NIH HHS
- NIOSH CDC HHS
- NIEHS NIH HHS
Zitieren
APA
Kadariya, Y., Sementino, E., Hua, X., Kappes, D. J., & Testa, J. R. (2025). Modeling Malignant Mesothelioma in Genetically Engineered Mice. Current Protocols, 5(1). https://doi.org/10.1002/cpz1.70086
Vancouver
Kadariya Y, Sementino E, Hua X, Kappes DJ, Testa JR. Modeling Malignant Mesothelioma in Genetically Engineered Mice. Current Protocols. 2025;5(1). doi:10.1002/cpz1.70086
BibTeX
@article{Kadariya2025,
author = {Kadariya, Yuwaraj and Sementino, Eleonora and Hua, Xiang and Kappes, Dietmar J and Testa, Joseph R},
title = {Modeling Malignant Mesothelioma in Genetically Engineered Mice},
journal = {Current Protocols},
year = {2025},
volume = {5},
number = {1},
doi = {10.1002/cpz1.70086}
}
EUVIMED